A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults

Overview

Journal J Clin Immunol

Publisher Springer

Specialty Allergy & Immunology

Date 2017 Sep 6

PMID 28871523

Citations 38

Authors

Bharat Kumar

Sohaib Aleem

Hana Saleh

Jennifer Petts

Zuhair K Ballas

Affiliations

Soon will be listed here.

Abstract

Objective: We assessed the clinical features and outcomes based on therapeutic options adopted during hospital stay for adult patients with macrophage activation syndrome and secondary hemophagocytic lymphohistiocytosis (MAS/sHLH).

Methods: We conducted a retrospective chart review of all adult patients (age ≥ 18 years) diagnosed with MAS/sHLH at our center between 2010 and 2015. Inclusion criteria for patients were diagnosis of MAS/sHLH during admission and patients meeting at least 5 out of 8 of Henter's criteria or at least 4 out of 6 of the criteria that were tested.

Results: Nineteen adult patients with MAS/sHLH met the inclusion criteria from January 2010 to October 2015 (median age 48 years; female 68.4%). Treatment had been personalized, depending on the clinical presentation and course of disease. Majority of the patients received anakinra, cyclosporine, intravenous immunoglobulins (IVIG), and steroids. Fourteen (74%) patients survived, with clinical improvement by the time of discharge. After excluding the three patients with underlying leukemia/lymphoma who opted for palliative care and subsequently died, the survival rate was 88%.

Conclusion: A modified diagnostic and treatment protocol for adult patients with MAS/sHLH that incorporated graded introduction of medications based on clinical presentation and cytokine profile resulted in the best adult survival rate reported in literature.

Citing Articles

Thrombocytopenia in Critically Ill Children: A Review for Practicing Clinicians.

Totapally B, Totapally A, Martinez P Children (Basel). 2025; 12(1).

PMID: 39857914 PMC: 11764412. DOI: 10.3390/children12010083.

Myeloma-associated hemophagocytic lymphohistiocytosis - A comprehensive case study and a novel chemotherapy-free approach with anakinra.

Al-Ammari M, Hsu D, Bryant A EJHaem. 2024; 5(5):1057-1062.

PMID: 39415906 PMC: 11474360. DOI: 10.1002/jha2.975.

Physiologically Based Pharmacokinetic Modelling in Critically Ill Children Receiving Anakinra While on Extracorporeal Life Support.

Dubinsky S, Hamadeh A, Imburgia C, McKnite A, Hunt J, Wong K Clin Pharmacokinet. 2024; 63(9):1343-1356.

PMID: 39331235 DOI: 10.1007/s40262-024-01424-w.

Hemophagocytic Lymphohistiocytosis Secondary to Acute Human Immunodeficiency Virus and COVID-19.

Chowdhury S, Sanekommu H, Gonzalez P, Angelova E, Patel S J Med Cases. 2024; 15(9):222-226.

PMID: 39205699 PMC: 11349122. DOI: 10.14740/jmc4226.

Hemophagocytic Lymphohistiocytosis Triggered by Herpes Simplex Virus 1 and 2: A Narrative Review.

Papazachariou A, Ioannou P Hematol Rep. 2024; 16(3):487-503.

PMID: 39189243 PMC: 11348265. DOI: 10.3390/hematolrep16030047.

References

Schulert G, Grom A . Pathogenesis of macrophage activation syndrome and potential for cytokine- directed therapies. Annu Rev Med. 2014; 66:145-59. PMC: 5846123. DOI: 10.1146/annurev-med-061813-012806. View

Shabbir M, Lucas J, Lazarchick J, Shirai K . Secondary hemophagocytic syndrome in adults: a case series of 18 patients in a single institution and a review of literature. Hematol Oncol. 2010; 29(2):100-6. DOI: 10.1002/hon.960. View

Mehta R, Smith R . Hemophagocytic lymphohistiocytosis (HLH): a review of literature. Med Oncol. 2013; 30(4):740. DOI: 10.1007/s12032-013-0740-3. View

Henter J, Horne A, Arico M, Egeler R, Filipovich A, Imashuku S . HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2006; 48(2):124-31. DOI: 10.1002/pbc.21039. View

Sato T, Mizue Terai , Tamura Y, Alexeev V, Mastrangelo M, Selvan S . Interleukin 10 in the tumor microenvironment: a target for anticancer immunotherapy. Immunol Res. 2011; 51(2-3):170-82. DOI: 10.1007/s12026-011-8262-6. View

Behrens E, Canna S, Slade K, Rao S, Kreiger P, Paessler M . Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest. 2011; 121(6):2264-77. PMC: 3104738. DOI: 10.1172/JCI43157. View

Brisse E, Wouters C, Matthys P . Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders. Cytokine Growth Factor Rev. 2014; 26(3):263-80. DOI: 10.1016/j.cytogfr.2014.10.001. View

Cron R, Davi S, Minoia F, Ravelli A . Clinical features and correct diagnosis of macrophage activation syndrome. Expert Rev Clin Immunol. 2015; 11(9):1043-53. DOI: 10.1586/1744666X.2015.1058159. View

Otrock Z, Eby C . Clinical characteristics, prognostic factors, and outcomes of adult patients with hemophagocytic lymphohistiocytosis. Am J Hematol. 2014; 90(3):220-4. DOI: 10.1002/ajh.23911. View

10.

Teachey D, Rheingold S, Maude S, Zugmaier G, Barrett D, Seif A . Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013; 121(26):5154-7. PMC: 4123427. DOI: 10.1182/blood-2013-02-485623. View

11.

Parikh S, Kapoor P, Letendre L, Kumar S, Wolanskyj A . Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014; 89(4):484-92. DOI: 10.1016/j.mayocp.2013.12.012. View

12.

Wang Y, Wang Z, Zhang J, Wei Q, Tang R, Qi J . Genetic features of late onset primary hemophagocytic lymphohistiocytosis in adolescence or adulthood. PLoS One. 2014; 9(9):e107386. PMC: 4169386. DOI: 10.1371/journal.pone.0107386. View

13.

Shakoory B, Carcillo J, Chatham W, Amdur R, Zhao H, Dinarello C . Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial. Crit Care Med. 2015; 44(2):275-81. PMC: 5378312. DOI: 10.1097/CCM.0000000000001402. View

14.

Orange J, Brodeur S, Jain A, Bonilla F, Schneider L, Kretschmer R . Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations. J Clin Invest. 2002; 109(11):1501-9. PMC: 150995. DOI: 10.1172/JCI14858. View

15.

Teachey D, Lacey S, Shaw P, Melenhorst J, Maude S, Frey N . Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discov. 2016; 6(6):664-79. PMC: 5448406. DOI: 10.1158/2159-8290.CD-16-0040. View

16.

Oto M, Yoshitsugu K, Uneda S, Nagamine M, Yoshida M . Prognostic Factors and Outcomes of Adult-Onset Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis of 34 Cases. Hematol Rep. 2015; 7(2):5841. PMC: 4508551. DOI: 10.4081/hr.2015.5841. View

17.

Miettunen P, Narendran A, Jayanthan A, Behrens E, Cron R . Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology (Oxford). 2010; 50(2):417-9. DOI: 10.1093/rheumatology/keq218. View

18.

Trottestam H, Horne A, Arico M, Egeler R, Filipovich A, Gadner H . Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood. 2011; 118(17):4577-84. PMC: 3208276. DOI: 10.1182/blood-2011-06-356261. View